NICE approve Pembroliziumab for adjuvant treatment for resected stage 2B or 2C melanoma

Melanoma Focus are delighted with the news that NICE have approved the recommendation of Pembroliziumab as an option of for the adjuvant treatment of completely resected stage 2B or 2C melanoma in people 12 years and over.

Our CEO, Susanna Daniels welcomed the news:

More than 16,000 people are diagnosed with melanoma every year. There have been huge medical advances in the field of melanoma over the last decade and immunotherapy treatment has been an integral to this. Fear of recurrence of cancer is also a huge emotional burden for patients and families and in particular for the growing population of melanoma patients who are diagnosed at a younger in age with the majority of their life ahead of them.  It is a mark of how far we have come in recent years that we can now substantially improve survival and significantly reduce those fears. I am thrilled that NICE have recognised the value this treatment adds for the adolescent and adult patients with high-risk stage 2 melanoma by reducing the likelihood of recurrence, and that it will now be available on a routine basis.”

You can read more here.

We have recently updated our illustrative visuals to explain the potential benefit of adjuvant treatment for 2B and stage 2C melanoma (recently approved by NICE TA837): see here.